Evidence map›Paper›PMID 34035117›Full record

ArticleScience immunology2021

Complement control for COVID-19.

Markus Bosmann

Open access · greenAbstract readComment
In one paragraph

Article in Science immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Complosome - the intracellular complement system.Nature reviews. Nephrology · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. The case of complement inhibitors.Advances in biological regulation · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Markus BosmannPulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, 02118, MA, USA. mbosmann@bu.edu.ORCID 0000-0003-2773-1033
Boston University · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Role reversal of MAVS in bacterial sepsisR01HL141513 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BOSMANN, MARKUS · 2018 to 2022
$2.4M
Bacterial polyphosphates in sepsisR01AI153613 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BOSMANN, MARKUS · 2021 to 2024
$2.1M
New genetic models for C5a receptorsR01HL139641 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BOSMANN, MARKUS · 2018 to 2022
$2.1M
NCATS NIH HHS UL1 TR001430NHLBI NIH HHS R01 HL139641NHLBI NIH HHS R01 HL141513NIAID NIH HHS R01 AI153613NIH HHS 1R01AI153613NIH HHS 1R01HL139641NIH HHS 1R01HL141513NIH HHS 1UL1TR001430
6 · The paper itself

Abstract

Excessive complement activation contributes to lung disease and adverse patient outcomes in COVID-19 (see the related Research Articles by Yan

Indexed as

COVID-19SARS-CoV-2Complement ActivationComplement System ProteinsHumansComplement System Proteins

Identifiers

PMID34035117
PMCPMC8432947
OpenAlexW3165837100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.